Abdominal Aortic Aneurysm Clinical Trial
Official title:
Endurant Evo US Clinical Trial
NCT number | NCT02393716 |
Other study ID # | 10173341DOC |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2015 |
Est. completion date | June 25, 2021 |
Verified date | November 2022 |
Source | Medtronic Cardiovascular |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to demonstrate that the Endurant Evo Abdominal Aortic Aneurysm (AAA) stent graft system is safe and effective for endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms.
Status | Terminated |
Enrollment | 139 |
Est. completion date | June 25, 2021 |
Est. primary completion date | June 25, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is =18 years old 2. Subject understands and voluntarily has signed and dated the Informed Consent approved by the Sponsor and by the Ethics Committee/Institutional Review Board 3. Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements 4. Subject is a suitable candidate for elective surgical repair of AAA as evaluated by American Society of Anesthesiologists (ASA) Physical Status Classification System I, II, or III 5. Subject has an infrarenal abdominal aortic or aortoiliac aneurysm characterized by one or more of the following: - Aneurysm is >5 cm in diameter (diameter measured is perpendicular to the line of flow) - Aneurysm is 4 - 5 cm in diameter and has increased in size =0.5 cm within the previous 6 months 6. Subject meets all the following anatomical criteria as demonstrated on contrast-enhanced computed tomography (CTA) or magnetic resonance angiography (MRA) imaging: - Proximal neck length of = 10 mm with = 60° infrarenal and = 45° suprarenal neck angulation or Proximal neck length of = 15 mm with = 75° infrarenal and = 60° suprarenal neck angulation - Subject has vascular dimensions, e.g., aortic and iliac diameters, lengths from renal arteries to iliac bifurcation and hypogastric arteries, in the range of sizes available for the Endurant Evo AAA stent graft system (measured intima to intima) and within the sizing recommendations (refer to Endurant Evo AAA stent graft system Instructions for Use (IFU)) - Subject has a proximal aortic neck diameter = 18 mm and = 32 mm - The distal fixation center of the iliac arteries must have a diameter = 7 mm and = 25 mm bilaterally for the bifurcation and unilaterally for the Aorto-uni-iliac stent graft (AUI) - Subject has documented imaging evidence of at least one patent iliac and one femoral artery, or can tolerate a vascular conduit that allows introduction of the Endurant Evo AAA stent graft system - Subject has distal non-aneurysmal iliac (cylindrical) fixation length =20 mm bilateral for the bifurcation and unilaterally for the AUI Exclusion Criteria: 1. Subject has a life expectancy =1 year 2. Subject is participating in another investigational drug or device study which would interfere with the endpoints and follow-ups of this study 3. Subject is pregnant 4. Subject has an aneurysm that is: - Suprarenal/pararenal/juxtarenal - Isolated ilio-femoral - Mycotic - Inflammatory - Pseudoaneurysm - Dissecting - Ruptured - Leaking but not ruptured 5. Subject requires emergent aneurysm treatment 6. Subject has a known, untreated thoracic aneurysm >4.5 cm in diameter at the time of screening 7. Subject has been previously treated for an abdominal aortic aneurysm 8. Subject has a history of bleeding diathesis or coagulopathy 9. Subject has had or plans to have an unrelated major surgical or interventional procedure within 1 month before or after implantation of the Endurant Evo AAA stent graft 10. Subject has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 3 months prior to implantation of the Endurant Evo AAA stent graft 11. Subject has a conical neck defined as a >4 mm distal increase from the lowest renal artery over a 10 mm length 12. Subject has a known allergy or intolerance to the device materials 13. Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment 14. Subject has significant aortic thrombus and/or calcification at either the proximal or distal attachment centers that would compromise fixation and seal of the device at the discretion of the investigator 15. Subject has ectatic iliac arteries requiring bilateral exclusion of hypogastric blood flow 16. Subject whose arterial access site is not anticipated to accommodate the diameter of the Endurant Evo AAA stent graft delivery system (13F-17F) due to vessel size, calcification, or tortuosity 17. Subject is morbidly obese or has other documented clinical conditions that severely inhibit radiographic visualization of the aorta at the discretion of the investigator 18. Subject has active infection at the time of the index procedure documented by e.g. pain, fever, drainage, positive culture and/or leukocytosis considered to be clinically significant per investigator discretion 19. Subject has congenital degenerative collagen disease, e.g., Marfan's Syndrome 20. Subject has a creatinine level > 2.00 mg/dl (or >176.8 µmol/L) 21. Subject is on dialysis |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan Health Sysem | Ann Arbor | Michigan |
United States | Heart Hospital of Austin | Austin | Texas |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | University of Virginia | Charlottesville | Virginia |
United States | Erlanger Medical Center | Chattanooga | Tennessee |
United States | The Christ Hospital | Cincinnati | Ohio |
United States | UPMC Pinnacle Harrisburg Campus | Harrisburg | Pennsylvania |
United States | Aurora St. Lukes Medial Center | Milwaukee | Wisconsin |
United States | Long Island Jewish Northshore University Hospital | New Hyde Park | New York |
United States | Maine Medical Center | Portland | Maine |
United States | Kaiser Permanente Zion Medical Center | San Diego | California |
United States | Providence Sacred Heart Medical Center | Spokane | Washington |
United States | Stanford Hospital & Clinics | Stanford | California |
United States | Medstar Heart & Vascular Institute | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Medtronic Cardiovascular |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Percentage of Subjects Experiencing a Major Adverse Event (MAE) Within 30 Days Post-implantation. | The percentage of subjects experiencing a Major Adverse Event (MAE) within 30 days post-implantation.
MAEs include the occurrence of any of the following events: All-cause mortality Bowel ischemia Myocardial infarction Paraplegia Procedural blood loss =1000 cc Renal failure Respiratory failure Stroke |
30-days | |
Primary | The Percentage of Subjects With Both Technical Success at the Time of Index Procedure and Treatment Success at 12-months Post-implantation. | Successful aneurysm treatment was achieved based on the following criteria:
Technical success at the index procedure (as assessed intra-operatively), defined as successful delivery and deployment of the Endurant Evo AAA Stent graft system in the planned location and with no unintentional coverage of both internal iliac arteries or any visceral aortic branches and with successful removal of the delivery system AND Treatment success consisting of freedom from: AAA diameter increase, defined as > 5 mm increase in maximum diameter as measured on computed tomography (CT) scan or magnetic resonance angiography/magnetic resonance imaging (MRA/MRI) at 12-month follow-up as compared to 1-month imaging Types I and III endoleaks at 12-month follow-up including those requiring intervention through 12 months Aneurysm rupture within 365 days Conversion to surgery within 365 days Stent graft migration resulting in a serious adverse event or requiring seco |
12-months | |
Secondary | All-cause Mortality | All-cause mortality (ACM) within 30, 183, 365 days | within 30, 183, and 365 days | |
Secondary | Aneurysm-related Mortality (ARM) | Aneurysm-related mortality (ARM) within 30, 183, and 365 days | within 30, 183, and 365 days | |
Secondary | Secondary Procedures to Correct Type I and III Endoleaks | Any reintervention procedure (surgical or endovascular) following the completion of the operative initial implantation procedure that is used to correct a Type I and III endoleaks within 183 and 365 days. Type I endoleak was defined as a leak resulting from an incomplete seal of the endograft proximally or distally and a Type III endoleak was defined as a leak resulting from a defect of fabric or between the segments of the modular graft (junctional endoleak. | within 183, and 365 days | |
Secondary | Secondary Procedures | Secondary procedures within 183 and 365 days | within 183, and 365 days | |
Secondary | Serious Adverse Events | Serious adverse events within 30, 183 and 365 days. | within 30, 183, and 365 days | |
Secondary | Conversion to Open Surgery | Conversion to open surgery within 183, and 365 days | within 183, and 365 days | |
Secondary | Aneurysm Rupture | Aneurysm rupture within 183 and 365 days | within 183 and 365 days | |
Secondary | Major Adverse Events | Major adverse events within 183 and 365 days | within 183 and 365 days | |
Secondary | Stent Graft Migration | Stent graft movement of either the main body or iliac limb distally or proximally at 6- and 12-month follow-up visits (as compared to 1-month imaging). Main body stent graft migration is defined as evidence of movement of the main body stent graft relative to fixed anatomic landmarks, which is not due to remodeling of the subject's vasculature. Migration is observed when the stent graft completely covers a renal artery or movement is > 10 mm either distally or proximally. Stent graft limb/extension migration is defined as evidence of a movement of the stent graft limbs/extensions relative to fixed anatomic landmarks, which is not due to remodeling of the subject's vasculature that is > 10 mm or coverage of the internal iliac artery. | At 6- and 12-month follow-up visits (as compared to 1-month imaging) | |
Secondary | Aneurysm Expansion >5 mm | Aneurysm expansion >5 mm at 6- and 12-month follow-up visits (as compared to 1-month imaging) | at 6- and 12-month follow-up visits (as compared to 1-month imaging) | |
Secondary | All Endoleaks Based on Imaging Findings | All endoleaks based on imaging findings at 1-month, 6-month and 12-month. An endoleak is defined by the presence of contrast-enhanced blood outside the lumen of the endoluminal graft but within the aneurysm sac as seen on computed tomography (CT), angiography, ultrasound, or other appropriate imaging modality. | at 1-, 6-, and 12-month follow-up visits | |
Secondary | Stent Graft Occlusions Based on Imaging Findings | Stent graft occlusions based on imaging findings through 1-, 6- and 12 months. Stent graft occlusion is defined as a 100% blockage of the lumen diameter of any implanted stent graft component(s) as evidenced by CT, angiography, ultrasound, or other appropriate imaging modality, and/or operative or pathological analysis. | Through 1-, 6- and 12 months | |
Secondary | Device Deficiencies Based on Imaging Findings | Device deficiencies based on imaging findings through 6- and 12 months. A device deficiency was defined according Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance (ref. ISO 14155:2011 3.15). | Through 6- and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04227054 -
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks
|
N/A | |
Active, not recruiting |
NCT03687489 -
Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System
|
N/A | |
Active, not recruiting |
NCT03507413 -
Metformin Therapy in Non-diabetic AAA Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05756283 -
The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair
|
N/A | |
Not yet recruiting |
NCT04089241 -
Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair
|
N/A | |
Active, not recruiting |
NCT02604303 -
A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
|
||
Completed |
NCT02229006 -
Sodium Fluoride Imaging of Abdominal Aortic Aneurysms
|
N/A | |
Terminated |
NCT01843335 -
Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair
|
N/A | |
Completed |
NCT02224794 -
LIFE Study: Least Invasive Fast-Track EVAR
|
||
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT01118520 -
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
|
Phase 2 | |
Terminated |
NCT01425242 -
Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension
|
N/A | |
Completed |
NCT00746122 -
Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
|
N/A | |
Completed |
NCT03952780 -
Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
|
||
Completed |
NCT00583414 -
Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
|
N/A | |
Recruiting |
NCT05864560 -
Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
|
||
Completed |
NCT01683084 -
Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
|
Phase 4 | |
Active, not recruiting |
NCT03180996 -
Global Fenestrated Anaconda Clinical sTudy
|
||
Completed |
NCT02493296 -
The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
|
||
Completed |
NCT03320408 -
Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
|